dCas9 fused to scFv (anti-spike)
(Plasmid
#186421)
-
PurposeExpression of dCas9 with C-terminal nanobody fusion recognizing spike protein from SARS-CoV-2
-
Depositing Lab
-
Sequence Information
-
Sequences (1) — Accept Affinity Reagent Sequence Policy
-
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 186421 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepdCas9-bacteria
-
Backbone manufacturerAddgene #44249 Stanley Qi
-
Vector typeCRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Chloramphenicol, 25 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namedCas9-scFv fusion (anti-SARS-CoV-2 spike)
-
SpeciesSynthetic
-
Insert Size (bp)4971
-
Tag
/ Fusion Protein
- 6His
Resource Information
-
A portion of this plasmid was derived from a plasmid made byBackbone derived from Addgene #44249 scFv fusion is B1-182.1 from Wang et al "Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants" Science 2021
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
dCas9 fused to scFv (anti-spike) was a gift from Stephen Elledge (Addgene plasmid # 186421 ; http://n2t.net/addgene:186421 ; RRID:Addgene_186421) -
For your References section:
CasPlay provides a gRNA-barcoded CRISPR-based display platform for antibody repertoire profiling. Barber KW, Shrock E, Elledge SJ. Cell Rep Methods. 2022 Oct 17;2(10):100318. doi: 10.1016/j.crmeth.2022.100318. eCollection 2022 Oct 24. 10.1016/j.crmeth.2022.100318 PubMed 36313802